Brokerages Expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to Post -$0.61 Earnings Per Share

Equities research analysts predict that Iovance Biotherapeutics, Inc. (NASDAQ:IOVAGet Rating) will announce earnings per share (EPS) of ($0.61) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.55). Iovance Biotherapeutics posted earnings per share of ($0.53) during the same quarter last year, which suggests a negative year-over-year growth rate of 15.1%. The firm is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($2.46) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($2.19). For the next year, analysts anticipate that the firm will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.81) to ($1.41). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVAGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.06. The firm had revenue of $12.00 million during the quarter. Iovance Biotherapeutics’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) EPS.

Several analysts have issued reports on IOVA shares. StockNews.com started coverage on Iovance Biotherapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial decreased their price objective on shares of Iovance Biotherapeutics from $32.00 to $29.00 in a report on Thursday, April 7th. Robert W. Baird upped their price objective on shares of Iovance Biotherapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, April 7th. Stifel Nicolaus upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and upped their price objective for the company from $23.00 to $25.00 in a report on Friday, January 28th. Finally, Chardan Capital reduced their price objective on Iovance Biotherapeutics from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, February 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Iovance Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $31.09.

NASDAQ:IOVA opened at $15.43 on Wednesday. The stock’s 50 day moving average price is $15.85 and its two-hundred day moving average price is $16.85. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -6.74 and a beta of 0.86. Iovance Biotherapeutics has a 12-month low of $11.91 and a 12-month high of $28.00.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Herold Advisors Inc. bought a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $33,000. Spire Wealth Management acquired a new position in Iovance Biotherapeutics in the first quarter valued at about $47,000. Lazard Asset Management LLC raised its stake in Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 934 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Iovance Biotherapeutics in the fourth quarter valued at about $55,000. Finally, Retirement Group LLC raised its stake in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 2,000 shares in the last quarter. 99.07% of the stock is owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics (Get Rating)

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.

See Also

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.